Boehringer's Gilotrif Gets FDA Approval for NSCLC

Boehringer Ingelheim announces approval of its first oncology drug
July 16, 2013
Add Us On Google
Boehringer Ingelheim announces approval of its first oncology drug after regulators in the USA gave the green light to Gilotrif for late-stage non-small cell lung cancer. Read the full story
Sign up for our eNewsletters
Get the latest news and updates

Related

Sponsored
Sponsored